Your browser doesn't support javascript.
loading
Specific oncogene activation of the cell of origin in mucosal melanoma.
Babu, Swathy; Chen, Jiajia; Robitschek, Emily; Baron, Chloé S; McConnell, Alicia; Wu, Constance; Dedeilia, Aikaterini; Sade-Feldman, Moshe; Modhurima, Rodsy; Manos, Michael P; Chen, Kevin Y; Cox, Anna M; Ludwig, Calvin G; Yang, Jiekun; Kellis, Manolis; Buchbinder, Elizabeth I; Hacohen, Nir; Boland, Genevieve M; Abraham, Brian J; Liu, David; Zon, Leonard I; Insco, Megan L.
Afiliação
  • Babu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Chen J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Robitschek E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Baron CS; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA.
  • McConnell A; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA.
  • Wu C; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA.
  • Dedeilia A; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA.
  • Sade-Feldman M; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA.
  • Modhurima R; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA.
  • Manos MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Chen KY; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA.
  • Cox AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Ludwig CG; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA.
  • Yang J; Broad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, 02142, USA.
  • Kellis M; MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, 02139, USA.
  • Buchbinder EI; Broad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, 02142, USA.
  • Hacohen N; MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, 02139, USA.
  • Boland GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Abraham BJ; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA.
  • Liu D; Broad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, 02142, USA.
  • Zon LI; Harvard Medical School (HMS), Boston, MA, USA; Department of Immunology, HMS, Boston, MA, 02115, USA.
  • Insco ML; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA.
bioRxiv ; 2024 Apr 26.
Article em En | MEDLINE | ID: mdl-38712250
ABSTRACT
Mucosal melanoma (MM) is a deadly cancer derived from mucosal melanocytes. To test the consequences of MM genetics, we developed a zebrafish model in which all melanocytes experienced CCND1 expression and loss of PTEN and TP53. Surprisingly, melanoma only developed from melanocytes lining internal organs, analogous to the location of patient MM. We found that zebrafish MMs had a unique chromatin landscape from cutaneous melanoma. Internal melanocytes could be labeled using a MM-specific transcriptional enhancer. Normal zebrafish internal melanocytes shared a gene expression signature with MMs. Patient and zebrafish MMs have increased migratory neural crest gene and decreased antigen presentation gene expression, consistent with the increased metastatic behavior and decreased immunotherapy sensitivity of MM. Our work suggests the cell state of the originating melanocyte influences the behavior of derived melanomas. Our animal model phenotypically and transcriptionally mimics patient tumors, allowing this model to be used for MM therapeutic discovery.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article